pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 11·1 min read
save

AI dependence mirrors addiction, warns psychiatrist, sparking debate on hidden costs

May 11, 2026·read at STAT ↗Neutral

Jonathan Avery, vice chair for addiction psychiatry at Weill Cornell Medicine, reflects on his podcast about addiction and the mixed feedback he receives.

In a recent episode he interviewed NYU neuroscientist Tim Requarth to explore how AI might become a participant in thinking and what hidden costs could arise from relying on it to ease mental effort.

Listeners reacted strongly, some calling the comparison of AI reliance to addiction alarmist, while others argued the technology is too valuable to question.

Avery notes that the debate itself, rather than a clear winner, highlighted how familiar the conversation about AI dependence has become, echoing patterns seen in substance dependence.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: What addiction medicine can teach us about depending on AI”

read at STAT ↗
1,059 words · retrieved May 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
New York University
topics
Psychiatry & CNS4ApprovalPain

related stories

  • Oct 5Biotech’s peptide shows promise as ‘bait molecule’ to treat neuropathic pain in miceFierce Biotech
  • Sep 21How J&J paved the way for Compass’ coming psychedelic drug launchBioPharma Dive
  • Sep 15STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseasesSTAT
  • Aug 19Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: AnalystsBioSpace
  • Jul 27MapLight dives despite positive data for schizophrenia drugBioPharma Dive